Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Gilead Sciences's enterprise value was $233.62B on Nov 11, 2026, against $173.80B a year earlier. Over the last 5 years it ranged from $94.58B to $234.80B, with a median of $124.80B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $233.62B | +37.5% |
| 2025 | Dec 31, 2025 | $169.95B | +27.6% |
| 2024 | Dec 31, 2024 | $133.22B | +11.9% |
| 2023 | Dec 29, 2023 | $119.07B | -6.4% |
| 2022 | Dec 30, 2022 | $127.19B | +12.5% |
| 2021 | Dec 31, 2021 | $113.07B | +44.3% |
| 2020 | Dec 31, 2020 | $78.34B | -6.9% |
| 2019 | Dec 31, 2019 | $84.13B | +5.2% |
| 2018 | Dec 31, 2018 | $79.94B | -15.8% |
| 2017 | Dec 29, 2017 | $94.92B | -13.7% |
| 2016 | Dec 30, 2016 | $109.97B | -28.4% |
| 2015 | Dec 31, 2015 | $153.67B | +5.2% |
| 2014 | Dec 31, 2014 | $146.06B | +21.0% |
| 2013 | Dec 31, 2013 | $120.74B | +92.0% |
| 2012 | Dec 31, 2012 | $62.89B | +118.3% |
| 2011 | Dec 30, 2011 | $28.81B | +2.7% |
| 2010 | Dec 31, 2010 | $28.05B | -26.1% |
| 2009 | Dec 31, 2009 | $37.98B | – |
See a number that looks wrong?